DAVENPORT & Co LLC Buys 34,391 Shares of The Cooper Companies, Inc. $COO

DAVENPORT & Co LLC lifted its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 770.1% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,857 shares of the medical device company’s stock after buying an additional 34,391 shares during the quarter. DAVENPORT & Co LLC’s holdings in Cooper Companies were worth $2,664,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in COO. GKV Capital Management Co. Inc. bought a new stake in Cooper Companies during the 1st quarter worth approximately $40,000. J.Safra Asset Management Corp boosted its position in shares of Cooper Companies by 204.8% in the second quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after purchasing an additional 340 shares during the period. CYBER HORNET ETFs LLC purchased a new stake in shares of Cooper Companies in the second quarter worth $36,000. MUFG Securities EMEA plc bought a new stake in shares of Cooper Companies during the 2nd quarter valued at $42,000. Finally, Assetmark Inc. raised its position in shares of Cooper Companies by 357.8% during the 2nd quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 483 shares during the period. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Stock Performance

NASDAQ:COO opened at $82.62 on Friday. The company has a market cap of $16.19 billion, a price-to-earnings ratio of 43.95, a PEG ratio of 2.36 and a beta of 1.05. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $100.24. The stock’s 50 day simple moving average is $75.92 and its two-hundred day simple moving average is $72.44. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. Cooper Companies’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period last year, the firm posted $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, equities analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies announced that its Board of Directors has initiated a share repurchase program on Wednesday, September 17th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical device company to repurchase up to 15.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Zacks Research raised multiple near‑ and medium‑term EPS forecasts (including FY2026 to $4.45, FY2027 to $4.84 and FY2028 to $5.33) and lifted several quarterly estimates — this improves the earnings trajectory and supports valuation multiple expansion.
• Positive Sentiment: Zacks specifically increased Q1 2026 to $1.02, Q2 2026 to $1.07, Q3 2026 to $1.16 and Q4 2026 to $1.20 (and raised several 2027 quarter estimates), signaling confidence in near‑term revenue/margin trends.
• Positive Sentiment: Brokerage consensus flagged a “Moderate Buy” for COO, which can attract incremental demand from models and investors that follow analyst ratings. Article Title
• Neutral Sentiment: A Zacks comparison piece examines COO vs. Merit Medical (MMSI) for value investors — useful for relative‑value decisions but not a direct catalyst. Article Title
• Neutral Sentiment: December short‑interest data in the report is effectively zero/NaN and appears unreliable; it provides no actionable signal on short pressure or squeeze risk at present.
• Negative Sentiment: One small downward tweak: Zacks trimmed Q3 2027 EPS from $1.25 to $1.24 — a minor cut that slightly offsets some upgrades but is not material to the overall upward revisions.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a research note on Friday, December 5th. Citigroup reissued a “neutral” rating and set a $88.00 target price (up previously from $72.00) on shares of Cooper Companies in a research note on Monday, December 8th. Stifel Nicolaus set a $95.00 price target on Cooper Companies and gave the stock a “buy” rating in a report on Friday, December 5th. The Goldman Sachs Group reaffirmed a “sell” rating and set a $71.00 price objective (up from $64.00) on shares of Cooper Companies in a report on Monday, December 8th. Finally, Morgan Stanley boosted their target price on shares of Cooper Companies from $76.00 to $83.00 and gave the stock an “equal weight” rating in a report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $90.15.

Insider Transactions at Cooper Companies

In related news, CEO Albert G. White III purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was bought at an average price of $80.80 per share, for a total transaction of $808,000.00. Following the completion of the transaction, the chief executive officer owned 236,151 shares in the company, valued at approximately $19,081,000.80. The trade was a 4.42% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Lawrence Erik Kurzius acquired 2,000 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were bought at an average price of $82.50 per share, for a total transaction of $165,000.00. Following the completion of the transaction, the director owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. This trade represents a 34.62% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 18,014 shares of company stock worth $1,441,196. 1.98% of the stock is currently owned by corporate insiders.

Cooper Companies Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.